Absci Corporation Common Stock ABSI
i
Market dataready · fetched 2026-11-11T15:39:34.970Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:39:06.18309336Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-11T15:39:34.472108+00:00
Absci Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 12.47 | 141.3% | 26.6% | |||
| 25Δ | 11.99 | 143.5% | 22.6% | 9.05 | 113.0% | 12.8% |
| 30Δ | 11.63 | 144.1% | 19.9% | 9.28 | 114.5% | 11.5% |
| 35Δ | 11.27 | 144.8% | 17.2% | 9.51 | 115.9% | 10.2% |
| 40Δ | 10.92 | 142.7% | 14.5% | 9.75 | 117.3% | 8.9% |
| 45Δ | 10.60 | 132.2% | 11.9% | 9.98 | 118.8% | 7.6% |
| 50Δ | 10.28 | 121.8% | 9.2% | 10.17 | 113.5% | 6.6% |
| 55Δ | 9.96 | 114.4% | 6.9% | 10.35 | 107.7% | 5.6% |
| 60Δ | 9.66 | 129.6% | 6.4% | 10.54 | 101.8% | 4.6% |
| 65Δ | 9.36 | 144.8% | 6.0% | 10.72 | 95.9% | 3.6% |
| 70Δ | 9.06 | 159.9% | 5.5% | 10.90 | 90.0% | 2.6% |
| 75Δ | 8.80 | 153.7% | 4.5% | 11.10 | 84.6% | 1.8% |
| 80Δ | 8.55 | 141.7% | 3.4% | 11.32 | 79.6% | 1.4% |
20Δ
- Pseudo strike
- 12.47
- IV
- 141.3%
- B/E move
- 26.6%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 11.99
- IV
- 143.5%
- B/E move
- 22.6%
- Pseudo strike
- 9.05
- IV
- 113.0%
- B/E move
- 12.8%
30Δ
- Pseudo strike
- 11.63
- IV
- 144.1%
- B/E move
- 19.9%
- Pseudo strike
- 9.28
- IV
- 114.5%
- B/E move
- 11.5%
35Δ
- Pseudo strike
- 11.27
- IV
- 144.8%
- B/E move
- 17.2%
- Pseudo strike
- 9.51
- IV
- 115.9%
- B/E move
- 10.2%
40Δ
- Pseudo strike
- 10.92
- IV
- 142.7%
- B/E move
- 14.5%
- Pseudo strike
- 9.75
- IV
- 117.3%
- B/E move
- 8.9%
45Δ
- Pseudo strike
- 10.60
- IV
- 132.2%
- B/E move
- 11.9%
- Pseudo strike
- 9.98
- IV
- 118.8%
- B/E move
- 7.6%
50Δ
- Pseudo strike
- 10.28
- IV
- 121.8%
- B/E move
- 9.2%
- Pseudo strike
- 10.17
- IV
- 113.5%
- B/E move
- 6.6%
55Δ
- Pseudo strike
- 9.96
- IV
- 114.4%
- B/E move
- 6.9%
- Pseudo strike
- 10.35
- IV
- 107.7%
- B/E move
- 5.6%
60Δ
- Pseudo strike
- 9.66
- IV
- 129.6%
- B/E move
- 6.4%
- Pseudo strike
- 10.54
- IV
- 101.8%
- B/E move
- 4.6%
65Δ
- Pseudo strike
- 9.36
- IV
- 144.8%
- B/E move
- 6.0%
- Pseudo strike
- 10.72
- IV
- 95.9%
- B/E move
- 3.6%
70Δ
- Pseudo strike
- 9.06
- IV
- 159.9%
- B/E move
- 5.5%
- Pseudo strike
- 10.90
- IV
- 90.0%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 8.80
- IV
- 153.7%
- B/E move
- 4.5%
- Pseudo strike
- 11.10
- IV
- 84.6%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 8.55
- IV
- 141.7%
- B/E move
- 3.4%
- Pseudo strike
- 11.32
- IV
- 79.6%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 113.89% | |
| 109.25% | |
| 125.54% | |
| 115.28% | |
| 120.29% | |
| 194.00% | |
| 109.58% | |
| 112.32% | |
| 110.89% | |
| 106.32% | |
| 104.34% | |
| 107.76% | |
| 108.60% | |
| 107.69% | |
| 109.61% | |
| 160.53% | |
| 101.58% | |
| 115.29% | |
| 113.98% | |
| 113.06% | |
| 111.31% | |
| 125.19% | |
| 125.68% | |
| 115.44% | |
| 191.33% | |
| 96.80% | |
| 100.58% | |
| 100.47% | |
| 112.32% | |
| 102.80% | |
| 97.42% | |
| 101.36% | |
| 101.94% | |
| 100.36% | |
| 100.39% | |
| 98.05% | |
| 103.80% | |
| 99.67% | |
| 107.74% | |
| 108.44% | |
| 116.91% | |
| 111.79% | |
| 112.91% | |
| 126.15% | |
| 119.97% | |
| 120.26% | |
| 147.97% | |
| 136.92% | |
| 137.70% | |
| 137.94% | |
| 135.90% | |
| 148.56% | |
| 141.94% | |
| 140.08% | |
| 140.83% |
Biotechnology
ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus…
More →ABVX
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in…
More →ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central…
More →ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston,…
More →ACHV
Description unavailable
More →ACIU
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative…
More →